Vaccine hope for sufferers of potentially fatal stomach bug

Scientists at The University of Nottingham have been awarded over 366,000 to help unravel the mystery of a stomach bug which causes gastric ulcers and cancer. Their research could lead to the development of a vaccine for those most at risk.

The bacterium, Helicobacter pylori (Hp), lives in the stomachs of approximately half the worlds population. Dr Karen Robinson, a lecturer at the Centre of Biomolecular Sciences and co-researcher John Atherton, Professor of Gastroenterology and Head of the Wolfson Digestive Diseases Centre, lead a team of scientists that have spent the last three years trying to discover why most people are immune to the bug while it can cause potentially fatal disease in some people.

Dr Robinson says this new funding, from the Medical Research Council, will allow them to address one of the most important questions in Helicobacter research why some infected individuals develop ulcers or gastric cancer whilst others remain asymptomatic. My interest is in the immune response and how this dictates whether or not an infected person goes on to develop disease.

In recent studies the team has shown that the bacteria induce changes to the immune system which calm the inflammation down. However, sometimes this relationship goes wrong. Their experiments showed that people with ulcers often have a suppressed protective response, leading to the development of severe inflammation and ulceration of the stomach lining.

If we become infected with Hp it generally happens in childhood. The bacteria can remain undetected in the stomach for life. However, in some people it causes inflammation which leads to gastric ulcers or cancer in later years. Scientists at The University of Nottingham believe the Hp manipulates the immune system and patients arent aware of a problem until the disease has become so advanced they need surgery or chemotherapy.

The occurrence of the disease is currently thought to be due to

Contact: Karen Robinson
University of Nottingham

Page: 1 2

Related biology news :

1. Vaccine trials inject hope into koalas future
2. Vaccine hope for malaria
3. Vaccine prevents prion disease in mice
4. Vaccine to cope with viral diversity in HIV
5. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
6. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
7. Vaccine-producing plant-factories
8. HPV Vaccine: Whats next
9. Vaccine shown effective against chancroid
10. Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax
11. Vaccine provides 100 percent protection against avian flu virus in animal study

Post Your Comments:

(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
Breaking Biology Technology:
Cached News: